# Early Onset Methylmalonic Aciduria and Homocystinuria cblC Type With Demyelinating Neuropathy 

Daniele Frattini, MD*, Carlo Fusco, MD*, Valentina Ucchino, MD*, Barbara Tavazzi, $\mathbf{P h D}^{\dagger}$, and Elvio Della Giustina, MD*


#### Abstract

Methylmalonic aciduria and homocystinuria, cblC type, is the most common inborn error of vitamin $B_{12}$ (cobalamin) metabolism. The recent cloning of the disease gene, MMACHC, has permitted genotypephenotype correlation. In a 1-year-old girl, compound heterozygous c.271dupA and c.616C $>T$ mutations in MMACHC were identified as causing an early onset methylmalonic aciduria and homocystinuria, cblC type, which was complicated by sensorimotor peripheral demyelinating neuropathy. © 2010 by Elsevier Inc. All rights reserved.

Frattini D, Fusco C, Ucchino V, Tavazzi B, Della Giustina E. Early onset methylmalonic aciduria and homocystinuria cblC type with demyelinating neuropathy. Pediatr Neurol 2010;43:135-138.


## Introduction

Patients with methylmalonic aciduria and homocystinuria have defective metabolism of vitamin $\mathrm{B}_{12}$ (cobalamin)
in its two metabolically active forms: methylcobalamin and adenosylcobalamin. Methylmalonic aciduria and homocystinuria, cblC type (OMIM \#277400), is the most frequent inborn error of vitamin $\mathrm{B}_{12}$ metabolism; based on the age of onset, two distinct clinical phenotypes (early onset and late onset) have been demonstrated [1,2]. In 2006, Lerner-Ellis et al. [3] reported the identification of a gene responsible for this disorder, located on chromosome region 1p34.1: MMACHC [methylmalonic aciduria (cobalamin deficiency) cblC type, with homocystinuria] (OMIM *609831). The functions of the MMACHC gene product are not completely understood, but it apparently acts as an intracellular trafficking cobalamin chaperone. Reported here are clinical and biochemical findings in a 1-year-old child with early onset methylmalonic aciduria and homocystinuria, cblC type, complicated by peripheral sensorimotor demyelinating neuropathy, who carried compound heterozygous c.271dupA and c. $616 \mathrm{C}>\mathrm{T}$ mutations in the MMACHC gene.

## Case Report

The patient, a girl, was the second child of healthy, nonconsanguineous Italian parents. She was born at the 37th gestational week with an uneventful delivery. Intrauterine growth retardation had been noticed since the seventh month of pregnancy. Her weight at birth was 2.150 kg (10th to 25th centile), and her head circumference was 30 cm ( $<3 \mathrm{rd}$ centile). Apgar scores were 7 and 8 at 1 and 5 minutes, respectively. She had poor sucking, feeding difficulties, and severe hypotonia from birth.

The child was presented at 7 months of age with marked hypotonia, converging strabismus, and psychomotor delay. Neurologic examination revealed poor eye contact, strabismus, horizontal nystagmus, microcephaly, and severe axial and segmental hypotonia with reduced movement and areflexia. Routine laboratory examination findings were normal for hemogram and for erythrocyte mean corpuscular volume, glucose, transaminase, vitamin $\mathrm{B}_{12}$, folate, ammonium, lactate, creatine kinase levels, celiac disease screening, and serum free thyroid hormones. Similarly, there were no abnormal findings from funduscopic examination, brainstem acoustic evoked potentials, and abdominal and cardiac ultrasound. Cranial magnetic resonance imaging revealed a mild delay in myelination, and electroencephalograms displayed poorly organized background activity with occasional spikes and wave over the left occipitoparietal regions. No seizures were noticed.

Because of severe hypotonia and areflexia, electrophysiologic studies in the upper and lower limbs were performed, revealing uniform and symmetric slowing of both sensory and motor conduction velocities and normal amplitude of the compound sensory nerve and muscle nerve potentials (Tables 1 and 2). Moreover, the sensory nerve action potential of sural, medial plantar, and superficial peroneal nerves was bilaterally absent (Table 2). No temporal dispersion was detected. Distal latency values were at the upper limit of normal range for age

[^0][^1](Tables 1 and 2). Electromyographic evaluation of the bilateral anterior tibial and gastrocnemius muscles was unremarkable.

Further investigations revealed elevated plasma homocysteine, at $160 \mu \mathrm{~mol} / \mathrm{L}$ (normal range, 2.6-10.3 $\mu \mathrm{mol} / \mathrm{L}$ ); markedly elevated urinary methylmalonic acid, at $600 \mu \mathrm{~g} / \mathrm{mg}$ creatinine (normal value, $<5 \mu \mathrm{~g} / \mathrm{mg}$ creatinine); and decreased plasma methionine, at $4 \mu \mathrm{~mol} / \mathrm{L}$ (normal range, $9-42 \mu \mathrm{~mol} / \mathrm{L}$ ). Studies on the patient's cultured skin fibroblasts revealed low incorporation of both $\left[{ }^{14} \mathrm{C}\right]$ propionate and $\left[{ }^{14} \mathrm{C}\right]$ methyltetrahydrofolate, slightly low uptake of $\left[{ }^{57} \mathrm{Co}\right]$ cyanocobalamin, and a decreased synthesis of both adenosylcobalamin and methylcobalamin.

The diagnosis of methylmalonic aciduria and homocystinuria, cblC type, was confirmed by mutational analysis, which demonstrated heterozygosity for the 271dupA and $616 \mathrm{C}>\mathrm{T}$ mutations in the $M M A C H C$ gene. Treatment with oral hydroxycobalamin, vitamin $\mathrm{B}_{6}$, folic acid, carnitine, and betaine slightly decreased metabolite levels, although without complete normalization and without clinical improvement.

At the age of 12 months, the patient's clinical course was complicated by interstitial pneumonia with severe progression of neurologic impairment. The patient died 4 days later of respiratory failure and cardiac arrest.

## Discussion

With more than 400 cases described, methylmalonic aciduria and homocystinuria, cblC type, is the most frequent inborn error of vitamin $\mathrm{B}_{12}$ metabolism [2]. Two clinical forms have been described, based on age at onset (namely, an early and a late onset form). The early onset form, with the appearance of symptoms within the first year of life, includes failure to thrive, feeding difficulties, mild dysmorphic features [4], and ophthalmologic and cardiac anomalies [5,6]. Neurologic symptoms of the early onset form include hypotonia, progressive developmental delay, microcephaly, myelopathy, seizures,

Table 1. Motor nerve conduction findings at age 7 months in a case of early onset methylmalonic aciduria and homocystinuria, cblC type, complicated by sensorimotor peripheral demyelinating neuropathy

| Measure | Patient Value | Normal Value |
| :---: | :---: | :---: |
| Right peroneal nerve |  |  |
| Conduction velocity, m/s | 30 | >31 |
| Response amplitude, mV | 3.5 | $>2$ |
| Distal latency, ms | 3.1 | <3.2 |
| Left peroneal nerve |  |  |
| Conduction velocity, m/s | 25 | $>31$ |
| Response amplitude, mV | 3.6 | $>2$ |
| Distal latency, ms | 3 | <3.2 |
| Right posterior tibial nerve |  |  |
| Conduction velocity, m/s | 22 | $>31$ |
| Response amplitude, mV | 7 | $>2$ |
| Distal latency, ms | 3 | <3.2 |
| Left posterior tibial nerve |  |  |
| Conduction velocity, m/s | 24 | >31 |
| Response amplitude, mV | 7.5 | >2 |
| Distal latency, ms | 3.1 | <3.2 |
| Left median nerve |  |  |
| Conduction velocity, m/s | 24 | >26 |
| Response amplitude, mV | 3 | $>2$ |
| Distal latency, ms | 2.6 | <3.2 |
| Right median nerve | not tested |  |

Table 2. Sensory nerve conduction findings at age 7 months in a case of early onset methylmalonic aciduria and homocystinuria, cblC type, complicated by sensorimotor peripheral demyelinating neuropathy

| Measure | Patient Value | Normal Value |
| :--- | :---: | :---: |
|  |  |  |
| Right median nerve |  |  |
| Conduction velocity, $\mathrm{m} / \mathrm{s}$ | 25 | $>39$ |
| Response amplitude, $\mu \mathrm{V}$ | 15 | $>14$ |
| Distal latency, ms | 2.2 | $<2.4$ |
| Left median nerve |  | $>39$ |
| Conduction velocity, $\mathrm{m} / \mathrm{s}$ | 15 | $>14$ |
| Response amplitude, $\mu \mathrm{V}$ | 1.8 | $<2.4$ |
| Distal latency, ms |  |  |
| Right ulnar nerve | 25 | $>34$ |
| Conduction velocity, $\mathrm{m} / \mathrm{s}$ | 12 | $<2.5$ |
| Response amplitude, $\mu \mathrm{V}$ | 1.9 |  |
| Distal latency, ms | not tested |  |
| Left ulnar nerve | no response |  |
| Sural nerve | no response |  |
| Medial plantar nerve | no response |  |
| Superficial peroneal nerve |  |  |

and hydrocephalus [1]. A milder phenotype is described in patients with the later onset form, in which behavioral disturbances and neurologic impairment are noticed after the age of 4 years [1,7].

In 2006, Lerner-Ellis et al. [3] reported the identification of $M M A C H C$, the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. Although this disorder has been demonstrated to be a heterogeneous condition, identification of the gene involved has allowed study of phenotype-genotype correlation. To date, 56 mutations have been detected in 366 individuals with methylmalonic aciduria and homocystinuria, cblC type. The most common mutation, c.271dupA (p.Arg91LysfsX14), accounts for $42 \%$ of all pathologic alleles; the second most common mutation, c.394C $>\mathrm{T}$ (p.R132X), represents $20 \%$ of affected alleles [2]. Individuals with $\mathrm{c} .394 \mathrm{C}>\mathrm{T}$ tend to present with late onset disease, whereas patients with c.271dupA tend to present in infancy. Moreover, in the published cases of patients homozygous for c.271dupA mutation [2,8,9], the phenotype was invariably early onset.

In the present case, mutational analysis of the MMACHC gene revealed compound heterozygosity for 271dupA and a missense mutation, $616 \mathrm{C}>\mathrm{T}$. In patients who are compound heterozygotic for c.271dupA and a missense mutation, the late onset variant of disease is frequently seen [2,8], suggesting that the transcripts containing these missense alleles are translated into proteins with residual function. In the cohorts reported, only a few individuals with early onset methylmalonic aciduria and homocystinuria, cblC type, were compound heterozygotic for the 271dupA mutation and a missense mutation [2,9].

The $\mathrm{c} .616 \mathrm{C}>\mathrm{T}$ (p.Arg206Trp) missense mutation found in the present case has been described previously only in
a homozygous Turkish patient with an early onset form of the disease [2]. To our knowledge, the present report is the first publication of a case with compound heterozygosity for the 271dupA and $616 \mathrm{C}>\mathrm{T}$ mutations in the MMACHC gene. Clinical heterogeneity and variability in phenotype and age of onset of disease may also be related to the presence of polymorphisms or mutations in other genes in the cobalamin pathway, or to cis-acting polymorphisms or trans-acting factors interacting with the mutant form of protein and environmental factors (e.g., diet). Moreover, individuals with later onset of the disease may have developed mild symptoms that went unrecognized for some time before the formal diagnosis [2,9].

In the present case, magnetic resonance imaging at the age of 7 months indicated delayed myelination, and electroneurographic studies revealed the presence of a demyelinating neuropathy. White matter damage and demyelination in central nervous system is a well established feature of methylmalonic aciduria and homocystinuria, cblC type, and cranial magnetic resonance imaging typically reveals diffuse supratentorial white matter swelling at presentation and a variably severe white matter loss at later stages of the disease, sometimes associated with delayed myelination [10]. In contrast, peripheral neuropathy is more frequently reported in the late onset form, and never in the early onset form. No detailed neurophysiologic studies are available for the late onset cases reported; nerve biopsy specimens display demyelinating [11], axonal [12], and mixed axonal and demyelinating peripheral neuropathy [13]. Although in the present case the lack of nerve biopsy complicates the precise diagnosis, electrophysiologic study indicated a sensorimotor demyelinating polyneuropathy. Despite slowing, the absence of temporal dispersion probably indicates a homogeneity of the pathologic process at this stage of the disease ( 7 months of age). Moreover, sensory nerve action potential was absent in the lower limbs, indicating a major involvement of sensory nerves at onset.

Several hypotheses have been put forward to explain the underlying mechanism of white matter involvement in methylmalonic aciduria and homocystinuria, cblC type. Disease results from combined impaired synthesis of adenosylcobalamin and methylcobalamin, the latter leading to decreased activity of methionine synthase and a subsequent reduced availability of methionine for conversion to the universal methyl donor $S$-adenosylmethionine [14]. Myelin basic protein, a major constituent in central and peripheral nervous system myelin, is believed to participate in the tight compaction of myelin sheath through association with acidic lipids on the cytosolic side of the membrane bilayer. Myelin basic protein is methylated by a specific methyltransferase requiring $S$-adenosylmethionine as the methyl donor [15]. A decrease in the methylation of myelin basic protein could cause conformational change and splitting of the myelin sheet, leading to peripheral demyelinating neuropathy. An alternative hypothesis is a reduction in the methylation of lipids required for maintenance of the myelin sheet [14]. Further potential mechanisms for
neurotoxicity and white matter involvement have been related to homocysteine accumulation, which is responsible for vascular endothelial damage or direct neurotoxicity.

In conclusion, clinical, biochemical, neurophysiologic, and molecular findings have been presented for a patient with early onset methylmalonic aciduria and homocystinuria, cblC type, who was compound heterozygous for the 271dupA and $616 \mathrm{C}>\mathrm{T}$ mutations in the $M M A C H C$ gene; the case was complicated by peripheral sensorimotor demyelinating neuropathy. The present findings expand the clinical spectrum of early onset methylmalonic aciduria and homocystinuria, cblC type, to include early onset sensorimotor demyelinating neuropathy among the neurologic symptoms. Further studies into disease mechanisms are warranted, to better understand the phenotypic presentation and to clarify genotype-phenotype correlations for this disorder.

The authors thank David S. Rosenblatt, MD, for his helpful comments and suggestions. Thanks go also to Mrs. Elena Bonini and Mrs. Giuliana Soncini for their technical assistance.

## References

[1] Rosenblatt DS, Aspler AL, Shevell MI, Pletcher BA, Fenton WA, Seashore MR. Clinical heterogeneity and prognosis in combined methylmalonic aciduria and homocystinuria (cblC). J Inherit Metab Dis 1997; 20:528-38.
[2] Lerner-Ellis JP, Anastasio N, Liu J, et al. Spectrum of mutations in $M M A C H C$, allelic expression, and evidence for genotype-phenotype correlations. Hum Mutat 2009;30:1072-81.
[3] Lerner-Ellis JP, Tirone JC, Pawelek PD, et al. Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type [Erratum in: Nat Genet 2006;38:957]. Nat Genet 2006;38: 93-100.
[4] Cerone R, Schiaffino MC, Caruso U, Lupino S, Gatti R. Minor facial anomalies in combined methylmalonic aciduria and homocystinuria due to a defect in cobalamin metabolism. J Inherit Metab Dis 1999;22:247-50.
[5] Gerth C, Morel CF, Feigenbaum A, Levin AV. Ocular phenotype in patients with methylmalonic aciduria and homocystinuria, cobalamin C type [Erratum in: J AAPOS 2009;13:223]. J AAPOS 2008;12:591-6.
[6] Profitlich LE, Kirmse B, Wasserstein MP, Diaz GA, Srivastava S. High prevalence of structural heart disease in children with cblC-type methylmalonic aciduria and homocystinuria. Mol Genet Metab 2009;98: 344-8.
[7] Tsai AC, Morel CF, Scharer G, et al. Late-onset combined homocystinuria and methylmalonic aciduria (cblC) and neuropsychiatric disturbance. Am J Med Genet 2007;143A:2430-4.
[8] Morel CF, Lerner-Ellis JP, Rosenblatt DS. Combined methylmalonic aciduria and homocystinuria (cblC): phenotype-genotype correlations and ethnic-specific observations. Mol Genet Metab 2006;88: 315-21.
[9] Nogueira C, Aiello C, Cerone R, et al. Spectrum of MMACHC mutations in Italian and Portuguese patients with combined methylmalonic aciduria and homocystinuria, cblC type. Mol Genet Metab 2008;93: 475-80.
[10] Rossi A, Cerone R, Biancheri R, et al. Early-onset combined methylmalonic aciduria and homocystinuria: neuroradiologic findings. AJNR Am J Neuroradiol 2001;22:554-63.
[11] Roze E, Gervais D, Demeret S, et al. Neuropsychiatric disturbances in presumed late-onset cobalamin C disease. Arch Neurol 2003; 60:1457-62.
[12] Gold R, Bogdahn U, Kappos L, et al. Hereditary defect of cobalamin metabolism (homocystinuria and methylmalonic aciduria) of juvenile onset. J Neurol Neurosurg Psychiatry 1996;60:107-8.
[13] Powers JM, Rosenblatt DS, Schmidt RE, et al. Neurological and neuropathologic heterogeneity in two brothers with cobalamin C deficiency. Ann Neurol 2001;49:396-400.
[14] Surtees R. Demyelination and inborn errors of the single carbon transfer pathway. Eur J Pediatr 1998;157(Suppl. 2): S118-21.
[15] Ghosh SK, Syed SK, Jung S, Paik WK, Kim S. Substrate specificity for myelin basic protein-specific protein methylase I. Biochim Biophys Acta 1990;1039:142-8.


[^0]:    From the *Child Neurology Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; and the Institute of Biochemistry and Clinical Biochemistry, Catholic University of Rome, Rome, Italy.

[^1]:    Communications should be addressed to:
    Dr. Frattini; Child Neurology Unit; Arcispedale Santa Maria Nuova; Viale Risorgimento 80; 42100 Reggio Emilia, Italy.
    E-mail: frattini.daniele@asmn.re.it
    Received December 28, 2009; accepted April 12, 2010.

